Proportion of carbapenem-resistant Enterobacterales with readily detectable beta-lactam resistance.
作者信息
Wilber Eli, Smith Gillian, Jacob Jesse T, Rebolledo Paulina A
机构信息
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Grady Health System, Atlanta, GA, USA.
出版信息
Antimicrob Steward Healthc Epidemiol. 2025 Aug 7;5(1):e179. doi: 10.1017/ash.2025.10072. eCollection 2025.
Abstract
摘要
相似文献
1
Proportion of carbapenem-resistant Enterobacterales with readily detectable beta-lactam resistance.对碳青霉烯类耐药且易检测到β-内酰胺耐药性的肠杆菌科细菌比例。
Antimicrob Steward Healthc Epidemiol. 2025 Aug 7;5(1):e179. doi: 10.1017/ash.2025.10072. eCollection 2025.
2
Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China.中国碳青霉烯类耐药肠杆菌科中厄他培南单耐药分离株的流行情况和特征。
Emerg Microbes Infect. 2024 Dec;13(1):2332658. doi: 10.1080/22221751.2024.2332658. Epub 2024 Apr 3.
3
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.西鲁巴坦与美罗培南联合使用时，对产碳青霉烯酶肠杆菌科细菌具有广谱β-内酰胺酶覆盖范围和强大的抗菌活性，包括对新型β-内酰胺/β-内酰胺酶抑制剂组合耐药的菌株。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0053325. doi: 10.1128/aac.00533-25. Epub 2025 Jul 25.
4
Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019.2019 年中国细菌耐药监测网（CHINET）研究：新型β-内酰胺类-β-内酰胺酶抑制剂复方制剂及对照药物对革兰阴性杆菌临床分离株的活性。
Microbiol Spectr. 2022 Aug 31;10(4):e0185422. doi: 10.1128/spectrum.01854-22. Epub 2022 Jul 12.
5
activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations.头孢地尔对欧洲肠杆菌科细菌的活性，包括对美罗培南和近期β-内酰胺/β-内酰胺酶抑制剂组合耐药的分离株。
Microbiol Spectr. 2024 Jun 21;12(8):e0418123. doi: 10.1128/spectrum.04181-23.
6
Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.碳青霉烯类药物在耐超广谱头孢菌素肠杆菌科感染中的应用 ：美国医院的回顾性队列研究及 IDSA 指南的影响。
Lancet Infect Dis. 2024 Aug;24(8):856-867. doi: 10.1016/S1473-3099(24)00149-X. Epub 2024 Apr 25.
7
In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa.新型β-内酰胺酶抑制剂FL058与美罗培南联合对产KPC或NDM的肠杆菌科细菌及铜绿假单胞菌的体外活性
Eur J Clin Microbiol Infect Dis. 2025 Aug 12. doi: 10.1007/s10096-025-05232-3.
8
Prognosis and Outcome of Carbapenem-Resistant Enterobacterales Bacteremia Managed With Ceftazidime-Avibactam and Aztreonam Combination Therapy in Tawam Hospital, UAE: A Retrospective Study.阿联酋塔瓦姆医院采用头孢他啶-阿维巴坦与氨曲南联合治疗耐碳青霉烯类肠杆菌科菌血症的预后及结局：一项回顾性研究
Cureus. 2025 Jun 10;17(6):e85689. doi: 10.7759/cureus.85689. eCollection 2025 Jun.
9
Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology.碳青霉烯类耐药肠杆菌科、碳青霉烯类耐药菌、产碳青霉烯酶肠杆菌科和产碳青霉烯酶菌：在新型抗生素和区域碳青霉烯酶流行病学时代，术语已过“保质期”。
Clin Infect Dis. 2020 Oct 23;71(7):1776-1782. doi: 10.1093/cid/ciaa122.
10
Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.美罗培南-巴坦的微生物学：一种用于耐碳青霉烯类肠杆菌科细菌感染的新型碳青霉烯类β-内酰胺酶抑制剂组合
Infect Dis Ther. 2020 Dec;9(4):757-767. doi: 10.1007/s40121-020-00350-1. Epub 2020 Oct 5.
本文引用的文献
1
Xpert Carba-R Assay on Flagged Blood Culture Samples: Clinical Utility in Intensive Care Unit Patients with Bacteremia Caused by .针对标记血培养样本的Xpert Carba - R检测：在重症监护病房由……引起菌血症患者中的临床应用
Indian J Crit Care Med. 2023 Sep;27(9):655-662. doi: 10.5005/jp-journals-10071-24533.
2
Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.产碳青霉烯酶与非产碳青霉烯酶肠杆菌科细菌感染的危险因素：一项病例对照研究。
Clin Microbiol Infect. 2023 May;29(5):629-634. doi: 10.1016/j.cmi.2023.01.005. Epub 2023 Jan 12.
3
Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017-2019.2017-2019 年荷兰耐碳青霉烯类和产碳青霉烯酶肠杆菌科细菌的流行病学研究。
Antimicrob Resist Infect Control. 2022 Apr 9;11(1):57. doi: 10.1186/s13756-022-01097-9.
4
Molecular Characterization of Carbapenem-Resistant Enterobacterales Collected in the United States.美国收集的耐碳青霉烯类肠杆菌科细菌的分子特征分析
Microb Drug Resist. 2022 Apr;28(4):389-397. doi: 10.1089/mdr.2021.0106. Epub 2022 Feb 16.
5
Do Inpatient Antimicrobial Stewardship Programs Help Us in the Battle Against Antimicrobial Resistance?住院患者抗菌药物管理项目有助于我们对抗抗菌药物耐药性吗？
Clin Infect Dis. 2021 Dec 6;73(11):e4454-e4462. doi: 10.1093/cid/ciaa1004.
6
Carbapenemase-Producing Organisms: A Global Scourge.产碳青霉烯酶的生物体：全球的祸害。
Clin Infect Dis. 2018 Apr 3;66(8):1290-1297. doi: 10.1093/cid/cix893.
Zotero 插件